Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ruxolitinib for itch and inflammation, while also outlining a comprehensive approach to chronic pruritus management.
Watch
Teledermatology Benefits Underserved Populations, Reduces Physician Burnout
March 10th 2025Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, advocates for teledermatology as a vital tool to enhance health care equity by improving access for underserved populations and reducing physician burnout.
Watch
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Baricitinib Shows Promise for Pediatric Alopecia in BRAVE-AA-PEDS Study
March 9th 2025Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing the balance between treatment efficacy and safety.
Watch
Tailoring Atopic Dermatitis Treatment and the Safety of Topical Therapies, Ruxolitinib
March 9th 2025Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing personalized care based on patient history and the favorable long-term safety profile of topical ruxolitinib.
Watch
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Addressing Social Determinants of Health Improves Dermatologic Care in Underserved Populations
March 8th 2025Rebecca Vasquez, MD, FAAD, University of Texas Southwestern Medical Center, emphasizes the necessity of addressing social determinants to improve dermatological care and access for underserved populations.
Watch
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More
Tech Advances for Ocular Conditions Could Revolutionize Care
March 5th 2025Advancements in ocular technology, teleretinal imaging, and low-vision aids, including artificial intelligence-powered smart glasses, were highlighted in research posters at the Southeastern Congress of Optometry 2025.
Read More
Experts Recount What Aspects of SECO Will Be Vital to Their Future Practice
Attendees and experts from the Southeastern Educational Congress of Optometry (SECO) 2025 meeting highlight research and sessions they will take away.
Watch
An Elevated Member Experience, More Education, and Martha Stewart at the AAD 2025 Annual Meeting
March 4th 2025Seemal R Desai, MD, FAAD, president of the American Academy of Dermatology (AAD), emphasized his commitment to enhancing the upcoming 2025 annual meeting by introducing new events and expanding educational offerings to better serve and engage members.
Read More
Advancing Care for Dry Eye and Corneal Conditions
March 1st 2025Advancements in dry eye care focus on improvements seen in patients treated with cyclosporine 0.09% following inadequate responses at a lower dose, and customizable scleral lenses offer a nonsurgical option for Salzmann nodular degeneration, enhancing vision and comfort.
Read More
Enhancing Retinal Disease Outcomes With Anti-VEGF Therapies
March 1st 2025New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients with more treatment options, optimizing timing, and introducing innovative administration methods.
Read More